DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2024)

Parkinson's Disease | Special Topics | Detailed, Expanded Analysis: Special Topics: Opportunity for Nonmotor Symptoms (US)

Parkinson's Disease | Special Topics | Detailed, Expanded Analysis: Special Topics: Opportunity for Nonmotor Symptoms (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – June 2019

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms—some of which are highly prevalent—including cognitive impairment, mood disorders, psychosis, sleep disruption, and autonomic dysfunction. Experts report that some nonmotor symptoms can be more disabling for PD patients than the characteristic motor symptoms and, for many of these symptoms, few good treatment options exist. Opportunity for premium pricing and limited competition has spurred pharma’s interest in PD nonmotor symptoms and a number of agents are in early-phase development. Understanding neurologists’ prioritization of these symptoms, current management strategies, and prescribers’ receptivity for new entrants is crucial for developers advancing new drugs for this understudied and underdeveloped market space.

Questions Answered

  • Which PD nonmotor symptoms are well-managed, and which are lacking effective interventions?
  • Which nonmotor symptoms are the most prevalent in PD? Which are most concerning, according to surveyed neurologists and interviewed experts?
  • What clinical factors would most influence neurologists’ willingness to prescribe new brands for nonmotor symptoms?
  • What are the top reasons why neurologists do or do not prescribe current brands specifically approved for nonmotor symptoms in PD?

Geographies: United States

Primary research: Survey of 100 neurologists

Key drugs covered: Northera, Nuplazid, rivastigmine, and others

Key nonmotor symptoms covered: Dementia, orthostatic hypotension, psychosis, sleep disruption, and others

Key insights provided:

  • Unmet need and market opportunity for new nonmotor treatments
  • Factors influencing management and treatment decisions for key nonmotor symptoms
  • Physician-reported treatment practices and patient shares for key nonmotor symptoms
  • Likely acceptance of new therapies for key nonmotor symptoms

Product Description

DRG’s Special Topics reports use quantitative primary research to assess evolving trends and market opportunities in dynamic disease areas. Insights from this report on Parkinson’s disease will help developers identify promising areas of development or licensing and gauge the competitiveness and sales potential of their assets in the PD market.

Table of contents

  • Detailed, Expanded Analysis: Special Topics: Opportunity for Nonmotor Symptoms (US)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Bethany Christmann, PhD
  • Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.

Purchase Report

Recent reports:
You may also be interested in: